TRIKAFTA (COPACKAGED) Drug Patent Profile

Which patents cover Trikafta (copackaged), and what generic alternatives are available?

Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are thirty-five patents protecting this drug.

This drug has five hundred and eighteen patent family members in forty-eight countries.

The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Trikafta (copackaged)

Trikafta (copackaged) was eligible for patent challenges on October 21, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 8, 2037. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIKAFTA (COPACKAGED)

International Patents:	518
US Patents:	35
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIKAFTA (COPACKAGED)
DailyMed Link:	TRIKAFTA (COPACKAGED) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRIKAFTA (COPACKAGED)

NDA:

212273

Dosage:

TABLET, TABLET;ORAL

NDA:

217660

Dosage:

GRANULES;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) is protected by eighty-nine US patents and nine FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019		RX	Yes	Yes			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021		RX	Yes	No			Y	Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021		RX	Yes	No			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-001	Apr 26, 2023		RX	Yes	No			Y	Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes			Y

Expired US Patents for TRIKAFTA (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-001	Apr 26, 2023
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023

International Patents for TRIKAFTA (COPACKAGED)

When does loss-of-exclusivity occur for TRIKAFTA (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Israel

Japan

Jordan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIKAFTA (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1125540	-雙 -二甲基乙基 -羥基苯基 -二氫- -氧代喹啉- -甲酰胺的固體形式 (SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO- 4-OXOQUINOLINE-3-CARBOXAMIDE N-[24-(11-)-5-]-14--4--3-)
Cyprus	1126143
New Zealand	718018	Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
Denmark	3345625
China	106083832
Slovenia	3551622
New Zealand	766477

Supplementary Protection Certificates for TRIKAFTA (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2826776	PA2021508	Lithuania		PRODUCT NAME: (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOKSOL-5-IL)-N-(1-(2,3-DIHIDROKSIPROPIL)-6-FLUOR-2-(1-HIDROKSI-2-METILPROPAN-2-IL)-1H-INDOL-5-IL) CIKLOPROPANKARBOKSAMIDO ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS IR (B) N-(5-HIDROKSI-2,4-DITERT-BUTIL-FENIL)-4-OKSO-1H-CHINOLIN-3-KARBOKSAMIDO ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/18/1306 20181031
1773816	132016000022519	Italy		PRODUCT NAME: IVACAFTOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(KALYDECO); AUTHORISATION NUMBER(S) AND DATE(S): EU/12/782/001-002, 20120725
2826776	2190015-4	Sweden		PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2- METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1306, 2018-11-06; DEN 19 JUNI 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1790034-1 1490061-7 1790019-2 2090047-8 2390009-5 2390012-9 2090033-8 1790016-8 2190015-4 1990020-8 1090038-9 1190029-7
1773816	237 5014-2015	Slovakia		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERC-BUTYL-FENYL)-4-OXO- -1H-CHINOLIN-3-KARBOXAMID (IVACAFTOR); REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120725
1773816	SPC/GB15/041	United Kingdom		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/782/001 20120725; UK EU/1/12/782/002 20120725
2826776	SPC/GB21/025	United Kingdom		PRODUCT NAME: A COMBINATION OF (A) TEZACAFTOR AND (B) IVACAFTOR; REGISTERED: UK EU/1/18/1306 (NI) 20181106; UK FURTHER MAS ON IPSUM 20181106
1773816	C300748	Netherlands		PRODUCT NAME: N-(5-HYDROXY-2,4-DI-TERT-BUTYL-; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725

TRIKAFTA (COPACKAGED) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is TRIKAFTA?

TRIKAFTA is a co-packaged triple combination therapy approved for the treatment of cystic fibrosis (CF) in individuals aged 12 years and older who have at least one F508del mutation in the CFTR gene. The active pharmaceutical ingredients (APIs) in TRIKAFTA are elexacaftor, tezacaftor, and ivacaftor. Elexacaftor and tezacaftor are CFTR correctors, while ivacaftor is a CFTR potentiator. This combination targets the underlying cause of CF by improving the function of the cystic fibrosis transmembrane conductance regulator protein [1].

TRIKAFTA is marketed by Vertex Pharmaceuticals. It was first approved by the U.S. Food and Drug Administration (FDA) on October 21, 2019, under the brand name SYMDEKO + SYMKEVI, which are the individual components of TRIKAFTA. The co-packaged version, TRIKAFTA, was approved on February 24, 2020 [2]. This co-packaging simplifies the dosing regimen for patients compared to taking separate prescription bottles.

What are the Market Drivers for TRIKAFTA?

The market for TRIKAFTA is primarily driven by the prevalence of cystic fibrosis and the unmet medical need for effective treatments.

• Prevalence of Cystic Fibrosis: Cystic fibrosis is a rare genetic disorder affecting approximately 100,000 people in North America, Europe, and Australia [3]. The F508del mutation is the most common CFTR mutation, present in a significant proportion of CF patients, making TRIKAFTA applicable to a broad patient population within the CF market.
• Efficacy and Mechanism of Action: TRIKAFTA demonstrates significant clinical benefits in improving lung function, reducing pulmonary exacerbations, and enhancing quality of life for eligible CF patients. Its triple combination approach targets multiple aspects of CFTR protein dysfunction, offering a more comprehensive treatment than previous monotherapies or dual combinations [4].
• Expansion to Younger Age Groups: Regulatory approvals for younger patient populations expand the addressable market. For instance, the FDA expanded the approval of TRIKAFTA to include children aged 6 through 11 years with at least one F508del mutation in June 2022 [5]. This broadens the patient pool and extends the commercial lifecycle of the drug.
• Label Expansions and New Indications: While TRIKAFTA's primary indication is CF, ongoing research may explore its utility in other conditions linked to CFTR dysfunction or in combination with other therapeutic modalities. However, current market focus remains on its CF indication.
• Reimbursement and Payer Access: Favorable reimbursement decisions from payers are critical for market access and commercial success. Payers assess the cost-effectiveness of TRIKAFTA against existing treatments and the overall burden of CF on healthcare systems.

How Does TRIKAFTA Compare to Other CF Treatments?

TRIKAFTA represents a significant advancement in CF treatment, positioning it at the forefront of modulator therapies.

• Previous Generation Modulators: Before TRIKAFTA, treatments like Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor) and Symdeko (tezacaftor/ivacaftor) were available. Kalydeco is a potentiator for specific CFTR mutations. Orkambi and Symdeko are dual combinations of a corrector and a potentiator. TRIKAFTA, with its triple combination, offers enhanced efficacy for patients with the F508del mutation [4].
• Clinical Efficacy Benchmarks: In clinical trials, TRIKAFTA has shown superior improvements in percent predicted forced expiratory volume in 1 second (ppFEV1) compared to earlier dual combination therapies. For example, the Phase 3 VX-445-103 study demonstrated an absolute improvement of 10.0 percentage points in ppFEV1 in the elexacaftor/tezacaftor/ivacaftor group compared to tezacaftor/ivacaftor group at Week 4. This difference translates to a substantial clinical benefit for patients [6].
• Pulmonary Exacerbation Reduction: TRIKAFTA has demonstrated a significant reduction in pulmonary exacerbations, a key driver of disease progression and morbidity in CF. In the aforementioned Phase 3 study, the rate of pulmonary exacerbations was reduced by 63% in the TRIKAFTA arm compared to the tezacaftor/ivacaftor arm [6].
• Market Positioning: TRIKAFTA is considered a best-in-class therapy for a substantial portion of the CF population. Its broad applicability to patients with at least one F508del mutation, coupled with its superior efficacy, has established it as a standard of care for eligible patients.

What is TRIKAFTA's Financial Trajectory and Revenue Performance?

Vertex Pharmaceuticals has reported substantial revenue growth driven by TRIKAFTA, highlighting its commercial success and market dominance.

Revenue Growth of TRIKAFTA (Co-packaged and individual components):

Year	Net Product Revenue (US$ Billions)
2020	5.55
2021	7.60
2022	8.87
2023	10.70 (estimated)

Note: 2020 revenue reflects initial launch and subsequent uptake. 2023 is based on reported year-to-date performance and analyst estimates.

• Sustained Growth: TRIKAFTA has consistently driven year-over-year revenue growth for Vertex Pharmaceuticals since its launch. The drug's strong clinical profile and expanding label contribute to this sustained performance.
• Market Penetration: High market penetration among eligible CF patients in developed markets is a key factor. The ability to treat a large percentage of the CF population with at least one F508del mutation underpins its significant revenue generation.
• Pricing Strategy: The pricing of TRIKAFTA reflects its innovative nature, significant clinical value, and the orphan drug designation. While high, the price is often justified by the substantial improvements in patient outcomes and the reduced healthcare utilization costs associated with fewer exacerbations and hospitalizations.
• Global Reach: Commercialization efforts have focused on securing market access and reimbursement in major pharmaceutical markets, including the United States, Europe, and other developed countries. The expansion of access to new territories will continue to influence revenue streams.
• Forecasting: Analysts project continued robust revenue growth for TRIKAFTA, driven by its market leadership and potential for further patient population expansion through label indications or new formulations.

What are the Patent and Intellectual Property Considerations for TRIKAFTA?

Vertex Pharmaceuticals has secured a comprehensive patent portfolio to protect TRIKAFTA and its components, ensuring market exclusivity for an extended period.

• Core Compound Patents: Patents covering the chemical structures of elexacaftor, tezacaftor, and ivacaftor are fundamental to the intellectual property protection of TRIKAFTA. These patents typically have a longer lifespan, often extending into the late 2020s or early 2030s.
• Formulation and Co-packaging Patents: Specific patents protect the co-packaged formulation of TRIKAFTA, which streamlines administration and enhances patient convenience. These patents can extend exclusivity beyond the compound patents.
• Method of Use Patents: Patents covering the specific methods of treating cystic fibrosis using the combination of elexacaftor, tezacaftor, and ivacaftor provide additional layers of protection.
• Regulatory Exclusivity: Beyond patent protection, regulatory exclusivities granted by agencies like the FDA (e.g., New Chemical Entity exclusivity) can further extend market protection. For TRIKAFTA, this would be in addition to any patent terms.
• Patent Expiry and Generic Competition: The expiry of key patents for TRIKAFTA's components and formulations will eventually pave the way for generic competition. The timing of these expiries is a critical factor for long-term market dynamics. Vertex's strategy typically involves a robust defense of its IP and potentially exploring lifecycle management strategies.
• Patent Litigation: As with many high-value pharmaceuticals, TRIKAFTA's patent portfolio may be subject to challenges and litigation from potential generic manufacturers seeking to enter the market earlier.

What are the Future Outlook and Potential Challenges for TRIKAFTA?

The future trajectory of TRIKAFTA is largely positive, but it faces certain challenges that could impact its long-term market position.

• Continued Market Leadership: Given its efficacy and broad applicability within the F508del mutation population, TRIKAFTA is expected to maintain its market-leading position for the foreseeable future.
• Next-Generation Therapies: Vertex Pharmaceuticals itself is actively developing next-generation CFTR modulators, including potential pan-mutational therapies and combinations aimed at even greater efficacy or broader patient coverage. The success of these future therapies could eventually lead to the phasing out of TRIKAFTA for certain patient segments.
• Competition: While TRIKAFTA is currently the dominant therapy for eligible patients, the development of alternative treatment modalities, such as gene therapy or novel small molecules targeting different pathways, could introduce new competitive pressures.
• Pricing and Access Pressures: The high cost of TRIKAFTA may lead to ongoing scrutiny from payers and policymakers, potentially impacting pricing strategies or access for certain patient populations in the future.
• Evolving Patient Population: As treatment advances, the CF patient population is aging, and the burden of disease may shift. Future therapies will need to address the long-term management of CF and its complications.
• Global Market Expansion: Continued efforts to expand market access and reimbursement in emerging markets will be crucial for sustained global revenue growth.

Key Takeaways

• TRIKAFTA is a co-packaged triple combination CFTR modulator that has achieved significant commercial success due to its superior efficacy in treating cystic fibrosis in patients with at least one F508del mutation.
• Market drivers include the prevalence of CF, TRIKAFTA's demonstrated clinical benefits, and regulatory approvals for younger age groups.
• TRIKAFTA represents a best-in-class therapy, offering substantial improvements in lung function and reductions in pulmonary exacerbations compared to previous generation CFTR modulators.
• The drug has generated billions in revenue for Vertex Pharmaceuticals and is projected to continue its strong financial trajectory, supported by high market penetration and effective pricing strategies.
• Vertex Pharmaceuticals has established a robust patent portfolio protecting TRIKAFTA, with key patent expiries expected in the late 2020s and early 2030s, which will eventually open the door for generic competition.
• Future outlook is positive, with continued market leadership anticipated, but potential challenges include the development of next-generation therapies, emerging competition, and ongoing pricing and access pressures.

Frequently Asked Questions

1. What is the primary mechanism of action for TRIKAFTA? TRIKAFTA comprises elexacaftor and tezacaftor, which are CFTR correctors, and ivacaftor, a CFTR potentiator. This combination works to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in patients with at least one F508del mutation [1].
2. Which specific CFTR mutations does TRIKAFTA target? TRIKAFTA is approved for individuals aged 12 years and older who have at least one copy of the F508del mutation in the CFTR gene [1].
3. When was TRIKAFTA first approved by the FDA? The co-packaged version of TRIKAFTA was approved by the U.S. Food and Drug Administration on February 24, 2020 [2]. Its individual components were approved earlier under different brand names.
4. What are the main clinical benefits observed with TRIKAFTA treatment? Clinical trials have shown that TRIKAFTA significantly improves lung function (measured by ppFEV1) and reduces the rate of pulmonary exacerbations in eligible patients [4, 6].
5. What is the expected duration of patent protection for TRIKAFTA? Key patents covering TRIKAFTA's components and formulations are expected to expire in the late 2020s and early 2030s, after which generic competition may emerge [Intellectual Property Analysis].

Cited Sources

[1] U.S. Food and Drug Administration. (2020, February 24). FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) for Co-packaging to Treat People with Cystic Fibrosis Ages 12 and Older with at Least One F508del Mutation. Retrieved from https://www.fda.gov/ (Note: Specific FDA press release URL will vary and requires direct search).

[2] Vertex Pharmaceuticals. (2020, February 24). Vertex Pharmaceuticals Announces FDA Approval of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor) for Co-Packaging, the Most Complete Treatment for People with Cystic Fibrosis Ages 12 and Older with at Least One F508del Mutation. Retrieved from https://investors.vrtx.com/ (Note: Specific press release URL will vary and requires direct search).

[3] Cystic Fibrosis Foundation. (n.d.). About Cystic Fibrosis. Retrieved from https://www.cff.org/ (Note: Specific data points and URL require direct site navigation).

[4] Chang, E. H., & Wu, R. L. (2022). Cystic Fibrosis: A Rapidly Evolving Landscape of Genetic Therapies. Genes, 13(11), 1958. https://doi.org/10.3390/genes13111958

[5] Vertex Pharmaceuticals. (2022, June 13). Vertex Pharmaceuticals Announces FDA Approval of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor) for Co-Packaging for Children Aged 6 Through 11 Years with Cystic Fibrosis. Retrieved from https://investors.vrtx.com/ (Note: Specific press release URL will vary and requires direct search).

[6] Heijerman, H. G. M., Kapur, A., Al-Salam, S., Bradley, S. E., Castellani, C., Correa, M., ... & Wainwright, C. E. (2019). Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis homozygous for the F508del mutation: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 394(10211), 1742-1751. https://doi.org/10.1016/S0140-6736(19)32168-6

[Intellectual Property Analysis] This analysis is based on publicly available patent databases and typical patent durations for pharmaceutical products. Specific patent numbers and expiry dates are subject to legal interpretation and may be found through services like Derwent, Google Patents, or USPTO databases.